Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADC MATCH
NCT06311214Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2025
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sacituzumab govitecan, enfortumab vedotin and trastuzumab deruxtecan in solid tumor (4 arms), sponsored by National Cancer Institute. Primary endpoints: Frequency of high protein expression in patients with high ribonucleic acid (RNA) expression of each antibody-drug conjugate target and Objective Response Rate up to 3 years. Started Mar 2025; status: recruiting.
02
Drugs
sacituzumab govitecanenfortumab vedotintrastuzumab deruxtecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06311214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06311214.